Parallel Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.23M | Sell |
92,563
-36,636
| -28% | -$958K | 0.03% | 302 |
|
|
2026
Q1 | $3.63M | Buy |
129,199
+42,667
| +49% | +$1.14M | 0.07% | 200 |
|
|
2025
Q4 | $2.15M | Sell |
86,532
-6,879
| -7% | -$173K | 0.04% | 280 |
|
|
2025
Q3 | $2.38M | Buy |
93,411
+1,066
| +1% | +$26.3K | 0.04% | 254 |
|
|
2025
Q2 | $2.24M | Sell |
92,345
-8,248
| -8% | -$192K | 0.04% | 253 |
|
|
2025
Q1 | $2.55M | Buy |
100,593
+5,547
| +6% | +$145K | 0.06% | 213 |
|
|
2024
Q4 | $2.52M | Sell |
95,046
-29,377
| -24% | -$797K | 0.06% | 227 |
|
|
2024
Q3 | $3.6M | Buy |
124,423
+16,243
| +15% | +$474K | 0.08% | 184 |
|
|
2024
Q2 | $3.03M | Buy |
108,180
+17,370
| +19% | +$478K | 0.08% | 188 |
|
|
2024
Q1 | $2.52M | Buy |
90,810
+26,703
| +42% | +$741K | 0.07% | 203 |
|
|
2023
Q4 | $1.85M | Sell |
64,107
-13,746
| -18% | -$416K | 0.05% | 218 |
|
|
2023
Q3 | $2.58M | Sell |
77,853
-13,956
| -15% | -$494K | 0.09% | 179 |
|
|
2023
Q2 | $3.37M | Buy |
91,809
+5,388
| +6% | +$210K | 0.11% | 150 |
|
|
2023
Q1 | $3.53M | Buy |
86,421
+6,230
| +8% | +$269K | 0.12% | 149 |
|
|
2022
Q4 | $4.11M | Buy |
80,191
+9,306
| +13% | +$446K | 0.18% | 86 |
|
|
2022
Q3 | $3.1M | Sell |
70,885
-3,691
| -5% | -$179K | 0.14% | 109 |
|
|
2022
Q2 | $3.91M | Buy |
74,576
+1,962
| +3% | +$100K | 0.18% | 85 |
|
|
2022
Q1 | $3.81M | Sell |
72,614
-10,075
| -12% | -$523K | 0.15% | 105 |
|
|
2021
Q4 | $4.88M | Buy |
82,689
+2,636
| +3% | +$131K | 0.18% | 92 |
|
|
2021
Q3 | $3.44M | Buy |
80,053
+5,503
| +7% | +$244K | 0.14% | 110 |
|
|
2021
Q2 | $2.92M | Buy |
74,550
+8,141
| +12% | +$317K | 0.12% | 126 |
|
|
2021
Q1 | $2.41M | Buy |
66,409
+1,331
| +2% | +$47.3K | 0.11% | 133 |
|
|
2020
Q4 | $2.4M | Sell |
65,078
-6,053
| -9% | -$222K | 0.13% | 126 |
|
|
2020
Q3 | $2.48M | Buy |
71,131
+1,805
| +3% | +$63.3K | 0.15% | 105 |
|
|
2020
Q2 | $2.15M | Buy |
69,326
+10,180
| +17% | +$346K | 0.14% | 114 |
|
|
2020
Q1 | $1.83M | Buy |
59,146
+19
| +0% | +$647 | 0.15% | 108 |
|
|
2019
Q4 | $2.2M | Buy |
59,127
+862
| +1% | +$30.7K | 0.16% | 107 |
|
|
2019
Q3 | $1.99M | Sell |
58,265
-5,192
| -8% | -$189K | 0.17% | 106 |
|
|
2019
Q2 | $2.61M | Buy |
63,457
+405
| +0.6% | +$16.1K | 0.25% | 66 |
|
|
2019
Q1 | $2.54M | Buy |
63,052
+1,448
| +2% | +$58K | 0.29% | 66 |
|
|
2018
Q4 | $2.55M | Buy |
61,604
+2,383
| +4% | +$98.9K | 0.36% | 53 |
|
|
2018
Q3 | $2.47M | Buy |
59,221
+1,205
| +2% | +$46.4K | 0.31% | 58 |
|
|
2018
Q2 | $2M | Buy |
58,016
+10,813
| +23% | +$370K | 0.29% | 60 |
|
|
2018
Q1 | $1.59M | Buy |
47,203
+70
| +0.1% | +$2.41K | 0.25% | 77 |
|
|
2017
Q4 | $1.62M | Buy |
47,133
+171
| +0.4% | +$5.83K | 0.27% | 72 |
|
|
2017
Q3 | $1.57M | Buy |
46,962
+4,119
| +10% | +$132K | 0.27% | 71 |
|
|
2017
Q2 | $1.35M | Sell |
42,843
-6,057
| -12% | -$191K | 0.25% | 75 |
|
|
2017
Q1 | $1.55M | Buy |
48,900
+5,063
| +12% | +$160K | 0.31% | 67 |
|
|
2016
Q4 | $1.35M | Buy |
+43,837
| New | +$1.34M | 0.32% | 63 |
|
Other funds holding PFE
Parallel Advisors's PFE Position: Q2 2026 in Review
Parallel Advisors reduced its Pfizer (PFE) stake by 28% in Q2 2026, selling an estimated $958K and leaving 92,563 shares worth $2.23M. The position accounts for 0.03% of the portfolio, ranked #302.
Parallel Advisors first reported a position in PFE in Q4 2016 and has held it in 39 quarters since. The position peaked at $4.88M in Q4 2021. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Parallel Advisors held 92,563 shares of Pfizer worth $2.23M as of Q2 2026.
- Parallel Advisors sold 36,636 Pfizer shares in Q2 2026, an estimated $958K.
- Pfizer made up 0.03% of Parallel Advisors's portfolio in Q2 2026, its #302 holding.
- Parallel Advisors first reported a position in Pfizer in Q4 2016 and has held it in 39 quarters since.
- Parallel Advisors's Pfizer position peaked at $4.88M in Q4 2021.
- 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.